Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

APOTEX CORP.

Filed by APOTEX CORP..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 18, 2025
Income
Not reported
Expenses
$300,000.00
Registrant
APOTEX CORP.
Filing UUID
cdbf2b57-2302-41be-8ff7-d8879e33b8a6
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MAN · Manufacturing

Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs.

HCR · Health Issues

Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; and Federal policy relating to the structure of the Department of Health and Human Services.

TAR · Tariff (miscellaneous tariff bills)

Executive Order 14231, Amendment to Duties To Address the Flow of Illicit Drugs Across our Northern Border, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Executive Order 14257, Regulating Imports With A Reciprocal Tariff To Rectify Practices That Contribute To Large And Persistent Annual United States Goods Trade Deficits, provisions relating to the exemption of pharmaceuticals from reciprocal tariffs; Federal policy relating to the Department of Commerce's Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [Docket No. 250414-006] and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreement from any tariffs implemented following the completion of the Section 232 investigation;

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.